L-Carnitine is often considered safe at appropriate doses
The goal is to find the dose that delivers the best balance of results with the fewest side effects
Sources Eli Lilly, "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" (May 21, 2026) TRIUMPH-1 topline: 28.3% at 80 weeks, 30.3% at 104 weeks, 45.3% achieving 30%+ weight loss Eli Lilly, "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials" (July 23, 2026) TRIUMPH-2 (20.8% at 12 mg, A1C up to -1.6%) and TRIUMPH-3 (22.6% at 12 mg) topline, plus the stated plan to submit a BLA to the FDA in Q1 2027 ClinicalTrials.gov NCT05929066 (TRIUMPH-1) Phase 3, status Completed, primary completion April 6, 2026 Eli Lilly Q4 2025 earnings call transcript (February 4, 2026) confirmed regulatory submission planned for 2026 Eli Lilly press releases and investor communications ClinicalTrials.gov (TRIUMPH program trial registrations) Jastreboff AM, et al
Cagrilintide Peptide Appetite Regulation & Metabolic Research Compound
